Italy's Recordati Industria Chimica e Farmaceutica SpA has completely acquired worldwide rights to two of Novartis AG's treatments for a rare disease in a $390 million deal.
The acquisition covers Switzerland-based Novartis' Cushing's disease drug Signifor and its extended-release version, Signifor LAR. It also includes global rights for the company's experimental drug osilodrostat, or LCI699, aimed to treat Cushing's syndrome, for which Novartis has filed marketing applications in the U.S. and Europe.
Cushing's is a severe endocrine disease caused by an enlargement in the pituitary gland that results in overproduction of the body's main stress hormone, cortisol.
As part of the deal, the Swiss pharmaceutical giant is also eligible for subsequent milestone payments tied to approval and market access of osilodrostat and royalties from the sales.
Recordati previously said it would fund the transaction from existing liquidity and new debt facilities.